NS5A Effect on HIV Replication
- 详细技术说明
- Researchersat the University of Iowa have discovered a new peptide capable of preventingor treating HIV infections. The isolatedpeptide in NS5A is a small, non-structural protein that has been identified todecrease HIV infectivity of T-cells. This peptide encompasses a 15-80 amino acidregion of flaviviral NS5A that limits the entry point of lymphocytes from theHIV virus. NS5A limits the entry pointof HIV into T-cells in late stage infections. Further research has shown that NS5A (via expression of a GBV-C NS5Aphosphoprotein) is regulating the cell-mediated immune response against the HIVvirus.
- *Abstract
-
Background Information
HumanImmunodeficiency Virus (HIV) requires novel antiretroviral therapies tosuppress the HIV virus. According to theWorld Health Organization, 36.9 million people are living with HIV/AIDSworldwide, and only 14.9 million people have access to HIV treatment. The HIV virus has demonstrated the ability toconsistently out-pace antiretroviral therapies. Consequently, treatment options against HIVinfection and the development of AIDS remain highly desirable.
Technology Summary
Researchersat the University of Iowa have discovered a new peptide capable of preventingor treating HIV infections. The isolatedpeptide in NS5A is a small, non-structural protein that has been identified todecrease HIV infectivity of T-cells. This peptide encompasses a 15-80 amino acidregion of flaviviral NS5A that limits the entry point of lymphocytes from theHIV virus. NS5A limits the entry pointof HIV into T-cells in late stage infections. Further research has shown that NS5A (via expression of a GBV-C NS5Aphosphoprotein) is regulating the cell-mediated immune response against the HIVvirus.
Advantages
· Noveland specificantiretroviraltherapy
· Virus-specificactivity: This therapy targets proteins expressed only by a viral host.Therefore, risks of side-effects and unexpected interactions are significantlyreduced
· Subunitof full-length viral protein: This peptide is significantly shorter than thefull-length NS5A protein, increasing delivery efficiency
· Prophylaxis& therapy options: The NS5A peptide can be used in prophylaxis to decreasethe likelihood of initial HIV infection or in therapy to decrease the rate atwhich the disease replicates
Publication
R.T. Rydze, J. Xiang, J. H. McLinden, and J. T. Stapleton, GB Virus Type CInfection Polarizes T-Cell Cytokine Gene Expression Toward a Th1 CytokineProfile via NS5A Protein Expression, J. INFECT DIS. (2012) 206 (1): 69-72.
http://jid.oxfordjournals.org/content/early/2012/05/10/infdis.jis312.full.pdf.
- *Licensing
- Mihaela D. BojinLicensing AssociateUniversity of Iowa Research FoundationEmail: mihaela-bojin@uiowa.eduPhone: 319-335-2723
- 国家/地区
- 美国
